Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pediatr Hematol Oncol. 2012 Sep;29(6):507-28. doi: 10.3109/08880018.2012.708707. Epub 2012 Aug 2.

Prospects and challenges of reprogrammed cells in hematology and oncology.

Author information

  • 1Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.

Abstract

Induced pluripotent stem cells (iPSCs) have emerged as a promising basis for modeling pediatric genetic disorders, allowing the derivation, study, and genetic correction of disease and patient-specific cell lines in vitro. Similar to embryonic stem cells (ESCs), iPSCs are capable of unlimited in vitro expansion and derivation of many cell types, including hematopoietic stem cells (HSCs). These may not only allow large scale screenings to develop therapeutic compounds, but also help to overcome cross-species barriers of genetically engineered animal models, which do not adequately recapitulate the associated human phenotype. Here, we review the current state and emerging developments of iPSC research, which can be exploited as a tool in modeling pediatric hematopoietic disorders and could lead to new clinical applications in gene and cell therapies.

PMID:
22857266
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk